{
    "nct_id": "NCT05410145",
    "age": "Adults",
    "cancer_center_accrual_goal_upper": 0,
    "curated_on": "2022-06-08",
    "study_start_date": "2022-08-03",
    "study_completion_date": "",
    "data_table4": "Interventional",
    "drug_list": {
        "drug": [
            {
                "drug_name": "Drug: Cisplatin"
            },
            {
                "drug_name": "Drug: Pembrolizumab"
            },
            {
                "drug_name": "Drug: D3S-001"
            },
            {
                "drug_name": "Drug: Pemetrexed"
            },
            {
                "drug_name": "Drug: Cetuximab"
            },
            {
                "drug_name": "Drug: Carboplatin"
            }
        ]
    },
    "long_title": "A Phase 1/2, Open Label, Dose-escalation, and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S 001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation",
    "last_updated": "2025-06-24",
    "management_group_list": {
        "management_group": [
            {
                "is_primary": "Y",
                "management_group_name": "Group1"
            }
        ]
    },
    "oncology_group_list": {
        "oncology_group": [
            {
                "group_name": "Group1",
                "is_primary": "N"
            }
        ]
    },
    "phase": "PHASE1",
    "principal_investigator": "NA",
    "principal_investigator_institution": "D3 Bio (Wuxi) Co., Ltd",
    "program_area_list": {
        "program_area": [
            {
                "is_primary": "Y",
                "program_area_name": "Program1"
            }
        ]
    },
    "protocol_id": 0,
    "protocol_ids": [],
    "protocol_no": "",
    "protocol_target_accrual": 442,
    "protocol_type": "INTERVENTIONAL",
    "prior_treatment_requirements": [
        "Inclusion:",
        "* Subject must have a histologically or cytologically confirmed metastatic or locally advanced solid tumor which is progressing.",
        "* Subject must have documented KRAS p.G12C mutation identified within the last 5 years by a local test on tumor tissue or blood.",
        "* Subject must have measurable disease per RECIST v1.1.",
        "* Subject must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.",
        "* Subject must have adequate organ and marrow function within the screening period.",
        "Exclusion:",
        "* Subject has any prior treatment with other treatments without adequate washout periods as defined in the protocol.",
        "* Subject has uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, uncontrolled or significant cardiovascular disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirements, substantially increase risk of incurring AEs, or compromise the ability of the subject to give written informed consent.",
        "* Subject has unresolved treatment-related toxicities from previous anticancer therapy of NCI CTCAE Grade \u22652 (with exception of vitiligo or alopecia).",
        "* Subject has active gastrointestinal disease or other that could interfere significantly with the absorption, distribution, metabolism, or excretion of oral therapy.",
        "* Concurrent participation in any clinical research study involving treatment with any investigational drug, radiotherapy, or surgery, except for the nontreatment phases of these studies (e.g., follow-up phase).",
        "Other protocol inclusion/exclusion criteria may apply"
    ],
    "short_title": "A Study of D3S 001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation",
    "site_list": {
        "site": []
    },
    "sponsor_list": {
        "sponsor": [
            {
                "is_principal_sponsor": "Y",
                "sponsor_name": "D3 Bio (Wuxi) Co., Ltd",
                "sponsor_protocol_no": "",
                "sponsor_roles": "sponsor"
            }
        ]
    },
    "staff_list": {
        "protocol_staff": []
    },
    "status": "open to accrual",
    "summary": "This is a first-in-human (FIH), multicenter, open-label, dose-escalation, and dose-expansion Phase 1/2 clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of D3S-001 or combination therapy in subjects with advanced KRAS p.G12C mutant solid tumors. D3S-001 will be taken daily by oral administration in 21-day treatment cycles.",
    "treatment_list": {
        "step": [
            {
                "step_internal_id": 111,
                "step_code": "1",
                "step_type": "Registration",
                "arm": [
                    {
                        "arm_code": "D3S-001 monotherapy",
                        "arm_internal_id": 0,
                        "arm_description": "Part 1: Dose Escalation, D3S-001 administered orally.\n\nPart 2 and Part 3a Arm C: Dose Expansion, D3S-001 administered orally in selected cancer type patients.\n\nPart 4a: Dose Optimization, D3S-001 administered orally in selected cancer type patients.",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: D3S-001",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            }
                        ]
                    },
                    {
                        "arm_code": "D3S-001 and pembrolizumab",
                        "arm_internal_id": 1,
                        "arm_description": "Part 3a Arm A: Dose Expansion, D3S-001 in combination therapy administered orally in selected cancer type patients.\n\nPembrolizumab administered intravenously.",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: D3S-001",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "1",
                                "level_description": "Drug: Pembrolizumab",
                                "level_internal_id": 1,
                                "level_suspended": "N"
                            }
                        ]
                    },
                    {
                        "arm_code": "D3S-001 and platinum doublet chemotherapy (cisplatin + pemetrexed or carboplatin + permetrexed)",
                        "arm_internal_id": 2,
                        "arm_description": "Part 3a Arm B: Dose Expansion, D3S-001 in combination therapy administered orally in selected cancer type patients.\n\nCisplatin + pemetrexed administered intravenously\n\nor\n\nCarboplatin + permetrexed administered intravenously",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: D3S-001",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "1",
                                "level_description": "Drug: Cisplatin",
                                "level_internal_id": 1,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "2",
                                "level_description": "Drug: Carboplatin",
                                "level_internal_id": 2,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "3",
                                "level_description": "Drug: Pemetrexed",
                                "level_internal_id": 3,
                                "level_suspended": "N"
                            }
                        ]
                    },
                    {
                        "arm_code": "D3S-001 and Cetuximab",
                        "arm_internal_id": 3,
                        "arm_description": "Part 3b: Dose Expansion, D3S-001 in combination therapy administered orally in selected cancer type patients.\n\nCetuximab administered intravenously.",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: D3S-001",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "1",
                                "level_description": "Drug: Cetuximab",
                                "level_internal_id": 1,
                                "level_suspended": "N"
                            }
                        ]
                    }
                ],
                "match": [
                    {
                        "and": [
                            {
                                "clinical": {
                                    "age_numerical": ">=18",
                                    "disease_status": [
                                        "Metastatic",
                                        "Locally Advanced",
                                        "Advanced"
                                    ],
                                    "oncotree_primary_diagnosis": "Pancreatic Adenocarcinoma"
                                }
                            },
                            {
                                "or": [
                                    {
                                        "genomic": {
                                            "hugo_symbol": "KRAS",
                                            "variant_category": "Mutation"
                                        }
                                    }
                                ]
                            }
                        ]
                    }
                ]
            }
        ]
    }
}